Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut du Cancer de Montpellier - Val d'Aurelle
Institut du Cancer de Montpellier - Val d'Aurelle
Abramson Cancer Center at Penn Medicine
Hoffmann-La Roche
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Poitiers University Hospital
The Netherlands Cancer Institute
Institut Curie
Assistance Publique - Hôpitaux de Paris
Austrian Breast & Colorectal Cancer Study Group
Washington University School of Medicine
Institut de Cancérologie de Lorraine
Institut Curie
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Institut du Cancer de Montpellier - Val d'Aurelle
Institut du Cancer de Montpellier - Val d'Aurelle
University Hospital Augsburg
Memorial Sloan Kettering Cancer Center
Centre Francois Baclesse
Centre Hospitalier Henri Duffaut - Avignon
UNICANCER
Washington University School of Medicine
Case Comprehensive Cancer Center
Institut Cancerologie de l'Ouest
Universitaire Ziekenhuizen KU Leuven
Centre Georges Francois Leclerc
Memorial Sloan Kettering Cancer Center
Centre Francois Baclesse, Luxembourg
University of Arkansas
Washington University School of Medicine
Hospices Civils de Lyon
Kahramanmaras Sutcu Imam University
Centre Leon Berard
University of Wisconsin, Madison
Washington University School of Medicine
Case Comprehensive Cancer Center
Centre Leon Berard
Vanderbilt-Ingram Cancer Center
Institut de Cancérologie de Lorraine
Gustave Roussy, Cancer Campus, Grand Paris
University of Virginia
Samsung Medical Center
Institut du Cancer de Montpellier - Val d'Aurelle
Instituto Nacional de Cancer, Brazil
SCRI Development Innovations, LLC
Vanderbilt-Ingram Cancer Center